A kit for detecting hepatitis C core antigen

Through magnetic microparticle chemiluminescence technology combined with immunomagnetic beads and chemiluminescence systems, a high-sensitivity HCV core antigen kit was developed, which solved the problem of insufficient detection sensitivity in the existing technology, and achieved efficient and accurate HCV core antigen detection. Important clinical and economic value.

CN118688455BActive Publication Date: 2024-11-12HUNAN DIGLOS BIOTECHNOLOGY CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411171377.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-12
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

The core antigen detection method for hepatitis C virus (HCV) in the prior art is insufficient in sensitivity and specificity, and cannot effectively diagnose and prevent infection in the early stage. It lacks efficient treatment methods and protective vaccines, which leads to a high possibility of reinfection.

Method used

Using magnetic microparticle chemiluminescence technology, through the binding of magnetic particles to anti-HCV-cAg antibodies, combined with immunomagnetic bead system and chemiluminescence system, a kit for high sensitivity and high specificity for HCV core antigens has been developed, including magnetic particles, The enzyme labeling system and luminescent substrate are coated with chitosan after carboxylation modification and boron oxide doping, increasing binding sites to improve detection accuracy.

Benefits of technology

It realizes high sensitivity and high specificity detection of HCV core antigens, which is simple and fast, improves the accuracy and sensitivity of detection, is suitable for early diagnosis and prevention, and has important clinical and economic value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention belongs to the field of biological detection technology, and specifically relates to a kit for detecting hepatitis C core antigen. The kit of the present invention comprises the following components: magnetic particle system: 0.1-0.2 M PBS buffer with pH=7.4-7.8 of magnetic particle and anti-HCV-cAg antibody linker; enzyme labeling system: 0.1-0.2 M PBS buffer with pH=7.4-7.8 of HRP-labeled anti-HCV-cAg antibody; luminescent substrate I: a mixture of 2.0-4.0 mmol / L luminol and 0.2-0.4 mmol / L p-iodophenol; luminescent substrate II: 5-10 mmol / L hydrogen peroxide. The kit prepared according to the method of the present invention has the characteristics of high sensitivity and high detection rate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological detection, and in particular, relates to a kit for detecting hepatitis C core antigen. Background Art

[0002] Hepatitis C virus (HCV) is a blood-borne virus. Persistent infection can develop into chronic hepatitis C, cirrhosis, and liver cancer. It can also cause many other related extrahepatic complications, especially metabolic disorders and cardiovascular diseases. There is no other effective treatment for chronic hepatitis C except interferon. After recovery from hepatitis C treatment, the serum antibody level is low and there is no immune protection. In addition, there is currently no protective vaccine available, so the possibility of reinfection is high.

[0003] Therefore, developing high-quality HCV core antigen detection reagents, early diagnosis of HCV and its infectious diseases, and timely intervention are of great significance to patient disease control and prognosis, and also have important clinical significance and economic value. Summary of the invention

[0004] The purpose of the present invention is to overcome the problems existing in the prior art and provide a kit for detecting hepatitis C core antigen and a preparation method thereof. The kit prepared according to the method of the present invention has the characteristics of high sensitivity and high detection rate.

[0005] The purpose of the present invention and the solution to the technical problem are achieved by adopting the following technical solutions.

[0006] One aspect of the present invention provides a kit for detecting hepatitis C core antigen, the kit comprising the following components:

[0007] Magnetic particle system: 0.1-0.2 M PBS buffer with pH=7.4-7.8 of magnetic particles and anti-HCV-cAg antibody conjugate;

[0008] Enzyme labeling system: HRP-labeled anti-HCV-cAg antibody in 0.1-0.2 M PBS buffer with pH=7.4-7.8;

[0009] Luminescent substrate I: a mixture of 2.0-4.0 mmol / L luminol and 0.2-0.4 mmol / L p-iodophenol;

[0010] Luminescent substrate II: 5-10 mmol / L hydrogen peroxide.

[0011] In a preferred embodiment of the present invention, the method for preparing the magnetic particles comprises the following steps:

[0012] The magnetic nanoparticles are ultrasonically dispersed in N,N-dimethylformamide, citric acid is added, and microwave treatment is performed at a power of 600 to 1000 W for 10 to 30 minutes, followed by filtering, washing and drying to obtain modified magnetic nanoparticles;

[0013] The modified magnetic nanoparticles are placed in a boron-containing mixed solution for ultrasonic treatment for 8 to 10 hours, during which ozone is continuously introduced, and then filtered, washed and dried to obtain boron oxide-doped modified magnetic nanoparticles;

[0014] Chitosan is dissolved in a hydrochloric acid solution with a volume fraction of 3-5% to obtain an acidified chitosan solution with a mass fraction of 5-10%, and then the modified magnetic nanoparticles doped with boron oxide are added and stirred evenly. A cross-linking monomer and an initiator are added and stirred to react at 100-150°C for 6-10 hours. After the reaction is completed, it is allowed to stand for 10-12 hours, and then filtered and washed to obtain magnetic particles with a diameter of 1-5 μm.

[0015] In a preferred embodiment of the present invention, the magnetic nanoparticles are selected from any one of Fe3O4, Fe2O3, and FeO.

[0016] In a preferred embodiment of the present invention, the citric acid is added in an amount with a mass ratio of 1 to 2:10 to the magnetic nanoparticles.

[0017] In a preferred embodiment of the present invention, the boron-containing mixed solution is a solution obtained by dissolving ammonium pentaborate and boric acid in water, wherein the ammonium pentaborate, boric acid and water are added in a mass ratio of 3: (5-10): 100.

[0018] In a preferred embodiment of the present invention, the boron oxide-doped modified magnetic nanoparticles are added in an amount with a mass ratio of 1:1 to 2 to chitosan.

[0019] In a preferred embodiment of the present invention, the crosslinking monomer is selected from any one of N,N'-alkylenebis(meth)acrylamide, ethylene glycol diacrylate or trimethylolpropane triacrylate.

[0020] In a preferred embodiment of the present invention, the initiator is selected from any one of cumene hydroperoxide, tert-butyl hydroperoxide and di-tert-butyl peroxide.

[0021] In a preferred embodiment of the present invention, the cross-linking monomer is added in a mass ratio of 1 to 3:1 with respect to chitosan; and the initiator is added in an amount of 0.3 to 0.5% of the mass of the cross-linking monomer.

[0022] In a preferred embodiment of the present invention, the kit further comprises a positive standard and a negative standard, the positive standard comprises HCV-cAg antigen, and the negative standard comprises BSA.

[0023] In a preferred embodiment of the present invention, the kit further comprises a sample diluent and a cleaning concentrate.

[0024] In a preferred embodiment of the present invention, the sample diluent is composed of: disodium hydrogen phosphate 1.974 g / L, potassium dihydrogen phosphate 0.2245 g / L, BSA 0.5 g / L, PC-300 0.1%;

[0025] The cleaning concentrate is composed of: 39.48 g / L disodium hydrogen phosphate, 4.49 g / L potassium dihydrogen phosphate, 18 g / L sodium chloride, and 0.5% Tween-20.

[0026] By means of the above technical solution, the present invention has at least the following advantages:

[0027] 1. The present invention combines the immunomagnetic bead system, the immune reaction system and the chemiluminescence system by using magnetic microparticle chemiluminescence technology to obtain a kit system for detecting HCV core antigen, which has the characteristics of high sensitivity, high specificity, simple and rapid operation.

[0028] 2. The magnetic particles of the present invention are independently developed products of this application, and have the advantages of high magnetism and good adsorption. They can achieve efficient binding with anti-HCV-cAg antibodies, increase the number of binding with anti-HCV-cAg antibodies, and thus improve the accuracy and sensitivity of detection.

[0029] 3. The magnetic particles used in the present invention are composite magnetic particles obtained by using magnetic nanoparticles as raw materials, undergoing carboxyl modification, boron oxide doping, and then polymerizing and coating chitosan. The magnetic particles of the present invention have multiple active binding sites, which can promote the binding with anti-HCV-cAg antibodies and increase the number of binding with anti-HCV-cAg antibodies, thereby improving the detection sensitivity and accuracy when actually used for HCV-cAg antigen detection.

[0030] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described in detail as follows. DETAILED DESCRIPTION

[0031] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Unless otherwise specified, the percentage content involved in the present invention refers to mass percentage for solid-liquid mixing and solid-solid mixing, and refers to volume percentage for liquid-liquid mixing.

[0033] Unless otherwise specified, the percentage concentrations referred to in the present invention all refer to final concentrations, which refer to the percentage of the added component in the system after the addition of the component.

[0034] The temperature parameters in the present invention, if not specifically limited, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the precision range controlled by the instrument.

[0035] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods.

[0036] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0037] Embodiment 1:

[0038] In this embodiment, a magnetic particle I is provided, and the preparation method thereof comprises the following steps:

[0039] The magnetic nanoparticles (Fe3O4) were ultrasonically dispersed in N,N-dimethylformamide, and then citric acid was added (at a mass ratio of 1.5:10 to the magnetic nanoparticles), and microwaved at 800 W for 20 min. The modified magnetic nanoparticles were then filtered, washed and dried.

[0040] Ammonium pentaborate, boric acid and water were mixed uniformly in a mass ratio of 3:7.5:100 to obtain a boron-containing mixed solution. The modified magnetic nanoparticles were placed in the boron-containing mixed solution for ultrasonic treatment for 9 hours in a mass volume ratio of 1g:20mL, during which ozone was continuously introduced at a rate of 7.5mL / min, and then filtered, washed and dried to obtain modified magnetic nanoparticles doped with boron oxide.

[0041] Chitosan was dissolved in a 4% hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 7.5%. Then, modified magnetic nanoparticles doped with boron oxide (added in a mass ratio of 1:1.5 to chitosan) were added and stirred evenly. N, N'-alkylenebis(methyl)acrylamide (added in a mass ratio of 2:1 to chitosan) and isopropylbenzene hydroperoxide (added in an amount of 0.4% of the mass of N, N'-alkylenebis(methyl)acrylamide) were added and stirred at 125°C for 8 hours. After the reaction was completed, the solution was allowed to stand for 11 hours, and then filtered and washed to obtain magnetic particles I with a diameter of 3 μm.

[0042] Embodiment 2:

[0043] In this embodiment, a magnetic particle II is provided, and the preparation method thereof comprises the following steps:

[0044] The magnetic nanoparticles (Fe2O3) were ultrasonically dispersed in N,N-dimethylformamide, and then citric acid was added (added in an amount according to a mass ratio of 1:10 to the magnetic nanoparticles), and microwaved at a power of 1000 W for 10 minutes. The modified magnetic nanoparticles were then filtered, washed and dried.

[0045] Ammonium pentaborate, boric acid and water were mixed uniformly in a mass ratio of 3:10:100 to obtain a boron-containing mixed solution. The modified magnetic nanoparticles were placed in the boron-containing mixed solution for ultrasonic treatment at a mass volume ratio of 1g:10mL for 10h, during which ozone was continuously introduced at a rate of 10mL / min, and then filtered, washed and dried to obtain modified magnetic nanoparticles doped with boron oxide.

[0046] Chitosan was dissolved in a 3% by volume hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 10%, and then the modified magnetic nanoparticles doped with boron oxide (added in a mass ratio of 1:1 to chitosan) were added and stirred evenly, and ethylene glycol diacrylate (added in a mass ratio of 3:1 to chitosan) and tert-butyl hydroperoxide (added in an amount of 0.5% of the mass of ethylene glycol diacrylate) were added and stirred at 100°C for 10 hours. After the reaction was completed, the solution was allowed to stand for 12 hours, and then filtered and washed to obtain magnetic particles II with a diameter of 1 μm.

[0047] Embodiment 3:

[0048] In this embodiment, a magnetic particle III is provided, and the preparation method thereof comprises the following steps:

[0049] The magnetic nanoparticles (Fe3O4) were ultrasonically dispersed in N,N-dimethylformamide, and then citric acid was added (added in an amount according to a mass ratio of 2:10 to the magnetic nanoparticles), and microwaved at a power of 600 W for 30 minutes. The modified magnetic nanoparticles were then filtered, washed and dried.

[0050] Ammonium pentaborate, boric acid and water were mixed uniformly in a mass ratio of 3:5:100 to obtain a boron-containing mixed solution. The modified magnetic nanoparticles were placed in the boron-containing mixed solution for ultrasonic treatment for 8 hours in a mass volume ratio of 1g:30mL, during which ozone was continuously introduced at a rate of 5mL / min, and then filtered, washed and dried to obtain modified magnetic nanoparticles doped with boron oxide.

[0051] Chitosan was dissolved in a 5% by volume hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 5%, and then the modified magnetic nanoparticles doped with boron oxide (added in a mass ratio of 1:2 to chitosan) were added and stirred evenly, and trimethylolpropane triacrylate (added in a mass ratio of 1:1 to chitosan) and di-tert-butyl peroxide (added in an amount of 0.3% of the mass of trimethylolpropane triacrylate) were added and stirred at 150°C for 6 hours. After the reaction was completed, the solution was allowed to stand for 10 hours, and then filtered and washed to obtain magnetic particles III with a diameter of 5 μm.

[0052] Embodiment 4:

[0053] In this embodiment, a magnetic particle IV is provided, and the preparation method thereof comprises the following steps:

[0054] Ammonium pentaborate, boric acid and water were mixed uniformly in a mass ratio of 3:7.5:100 to obtain a boron-containing mixed solution. Magnetic nanoparticles (Fe3O4) were placed in the boron-containing mixed solution for ultrasonic treatment for 9 hours in a mass volume ratio of 1g:20mL, during which ozone was continuously introduced at a rate of 7.5mL / min, and then filtered, washed and dried to obtain boron oxide-doped magnetic nanoparticles.

[0055] Chitosan was dissolved in a 4% hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 7.5%, and then boron oxide-doped magnetic nanoparticles (added in a mass ratio of 1:1.5 to chitosan) were added and stirred evenly. N, N'-alkylenebis(methyl)acrylamide (added in a mass ratio of 2:1 to chitosan) and isopropylbenzene hydroperoxide (added in an amount of 0.4% of the mass of N, N'-alkylenebis(methyl)acrylamide) were added and stirred at 125°C for 8 hours. After the reaction was completed, the solution was allowed to stand for 11 hours, and then filtered and washed to obtain magnetic particles IV with a diameter of 3 μm.

[0056] Embodiment 5:

[0057] In this embodiment, a magnetic particle V is provided, and the preparation method thereof comprises the following steps:

[0058] The magnetic nanoparticles (Fe3O4) were ultrasonically dispersed in N,N-dimethylformamide, and then citric acid was added (at a mass ratio of 1.5:10 to the magnetic nanoparticles), and microwaved at 800 W for 20 min. The modified magnetic nanoparticles were then filtered, washed and dried.

[0059] Chitosan was dissolved in a 4% hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 7.5%. Modified magnetic nanoparticles were then added (added at a mass ratio of 1:1.5 to chitosan) and stirred evenly. N, N'-alkylenebis(methyl)acrylamide (added at a mass ratio of 2:1 to chitosan) and isopropylbenzene hydroperoxide (added in an amount of 0.4% of the mass of N, N'-alkylenebis(methyl)acrylamide) were added and stirred at 125°C for 8 hours. After the reaction was completed, the solution was allowed to stand for 11 hours, and then filtered and washed to obtain magnetic particles V with a diameter of 3 μm.

[0060] Embodiment 6:

[0061] In this embodiment, a magnetic particle VI is provided, and the preparation method thereof comprises the following steps:

[0062] The magnetic nanoparticles (Fe3O4) were ultrasonically dispersed in N,N-dimethylformamide, and then citric acid was added (at a mass ratio of 1.5:10 to the magnetic nanoparticles), and microwaved at 800 W for 20 min. The modified magnetic nanoparticles were then filtered, washed and dried.

[0063] Ammonium pentaborate, boric acid and water were mixed uniformly in a mass ratio of 3:7.5:100 to obtain a boron-containing mixed solution. The modified magnetic nanoparticles were placed in the boron-containing mixed solution for ultrasonic treatment for 9 hours in a mass volume ratio of 1g:20mL, during which ozone was continuously introduced at a rate of 7.5mL / min, and then filtered, washed and dried to obtain modified magnetic nanoparticles doped with boron oxide.

[0064] Chitosan was dissolved in a 4% by volume hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 7.5%, and then the modified magnetic nanoparticles doped with boron oxide (added in a mass ratio of 1:1.5 to chitosan) were added and stirred evenly, and then allowed to stand for 11 hours. After filtering and washing, magnetic particles VI with a diameter of 3 μm were obtained.

[0065] Embodiment 7:

[0066] In this embodiment, a magnetic particle VII is provided, and the preparation method thereof comprises the following steps:

[0067] Chitosan was dissolved in a 4% hydrochloric acid solution to obtain an acidified chitosan solution with a mass fraction of 7.5%. Then, magnetic nanoparticles Fe3O4 (added in a mass ratio of 1:1.5 to chitosan) were added and stirred evenly. N, N'-alkylenebis(methyl)acrylamide (added in a mass ratio of 2:1 to chitosan) and isopropylbenzene hydroperoxide (added in an amount of 0.4% of the mass of N, N'-alkylenebis(methyl)acrylamide) were added and stirred at 125°C for 8 hours. After the reaction was completed, the solution was allowed to stand for 11 hours. After filtering and washing, magnetic particles VII with a diameter of 3 μm were obtained.

[0068] Embodiment 8:

[0069] In this embodiment, a magnetic particle VIII is provided, and the preparation method thereof comprises the following steps:

[0070] The magnetic nanoparticles (Fe3O4) were ultrasonically dispersed in N,N-dimethylformamide, and then citric acid was added (at a mass ratio of 1.5:10 to the magnetic nanoparticles), and microwaved at 800 W for 20 min. The modified magnetic nanoparticles were then filtered, washed and dried.

[0071] Ammonium pentaborate, boric acid and water were mixed uniformly in a mass ratio of 3:7.5:100 to obtain a boron-containing mixed solution. The modified magnetic nanoparticles were placed in the boron-containing mixed solution for ultrasonic treatment at a mass volume ratio of 1g:20mL for 9 hours, during which ozone was continuously introduced at a rate of 7.5mL / min, and then filtered, washed and dried to obtain magnetic particles VIII with a diameter of 3μm.

[0072] Embodiment 9:

[0073] In this embodiment, the composition and preparation method of kit 1 are provided, including:

[0074] 1. Preparation of magnetic particle system: Wash the magnetic particles three times with 0.1M pH=7.6 PBS buffer, and then resuspend the washed magnetic particles I with 0.1M pH=7.6 PBS buffer to obtain a magnetic particle suspension with a concentration of 2mg / L. Add anti-HCV-cAg antibody (CP9) to the magnetic particle suspension at a coating amount of 10ug / mg, vortex mix, and roll at room temperature for 30min. Add 10mM vitamin H (1mg of magnetic beads plus 50uL of vitamin H blocking solution) to the solution obtained after rolling reaction, vortex mix, and roll at room temperature for 30min. Finally, wash the above magnetic particles three times with 0.1M pH=7.6 PBS buffer, and then resuspend the washed magnetic particles with 0.1M pH=7.6 PBS buffer to obtain a 0.1M pH=7.6 PBS buffer magnetic particle system of magnetic particles and anti-HCV-cAg antibody conjugates with a concentration of 2g / L.

[0075] 2. Preparation of enzyme labeling system: The specific preparation method refers to the content disclosed in patent application CN201410740936.8, which is incorporated herein by reference. Finally, an enzyme labeling system of 0.1M pH=7.6 PBS buffer with HRP labeled anti-HCV-cAg antibody at a concentration of 2 g / L was obtained.

[0076] 3. Luminescent substrate I: a mixture of 3.0 mmol / L luminol and 0.3 mmol / L p-iodophenol.

[0077] 4. Luminescent substrate II: 7.5mmol / L hydrogen peroxide.

[0078] 5. Positive standard: HCV-cAg antigen at a concentration of 100 ng / mL in 0.1 M PBS buffer with a pH of 7.6.

[0079] 6. Negative standard: 100 ng / mL BSA in 0.1 M PBS buffer with pH = 7.6.

[0080] 7. The composition of the sample diluent is: disodium hydrogen phosphate 1.974 g / L, potassium dihydrogen phosphate 0.2245 g / L, BSA 0.5 g / L, PC-300 0.1% (volume fraction). All components are dissolved in double distilled water to prepare a mixed solution.

[0081] 8. The composition of the cleaning concentrate is: disodium hydrogen phosphate 39.48 g / L, potassium dihydrogen phosphate 4.49 g / L, sodium chloride 18 g / L, Tween-20 0.5% (volume fraction). All components are dissolved in double distilled water to prepare a mixed solution.

[0082] 9. The composition of the pretreatment solution is: 0.3% (volume fraction) TritonX100, 1.5% (mass fraction) SDS, 0.1M Tris-HCl buffer with pH=8.0. All components are dissolved in double distilled water to prepare a mixed solution.

[0083] The composition and preparation method of kits II to VIII refer to kit I, except that the magnetic particles used are the magnetic particles II to VIII prepared in Examples 2-8, respectively.

[0084] Embodiment 10:

[0085] In this embodiment, a detection method of a kit is provided, comprising the following steps:

[0086] (1) Equilibrate the samples and reagents in the kit at room temperature for 30 minutes;

[0087] (2) diluting the cleaning concentrate 20 times with distilled water to obtain a washing solution;

[0088] (3) Mix the pretreatment solution and the sample to be tested in a volume ratio of 1:2, incubate at 56°C with shaking for 30 min, and set aside;

[0089] (4) Preset blank control group, negative control group, positive control group and test group. Add 50 μL sample diluent, 100 μL enzyme labeling system and 200 μL magnetic particle system to the blank control group, add 50 μL negative standard, 100 μL enzyme labeling system and 200 μL magnetic particle system to the negative control group, add 50 μL positive standard, 100 μL enzyme labeling system and 200 μL magnetic particle system to the positive control group, and add 50 μL of the above incubated sample, 100 μL enzyme labeling system and 200 μL magnetic particle system to the test group. After addition, incubate at 37°C with shaking for 60 min.

[0090] (5) Wash the magnetic beads five times with washing solution in a magnetic field;

[0091] (6) Add 50 μL of luminescent substrates I and II to each group, incubate at room temperature for 5 min, and finally detect the luminescence intensity.

[0092] The critical value is the average RLU value of the negative standard test × 2.1; if the RLU value of the sample to be tested is greater than the critical value, the result is judged to be positive; if the RLU value of the sample to be tested is less than the critical value, the sample to be tested is judged to be negative.

[0093] Embodiment 11:

[0094] In this example, the sensitivity of the kits I to VIII obtained in Example 9 was tested. First, the positive standard was gradiently diluted to concentrations of 100 ng / mL, 50 ng / mL, 30 ng / mL, 10 ng / mL, 5 ng / mL, 3ng / mL, 1 ng / mL, 0.5 ng / mL, 0.3 ng / mL, and 0.1 ng / mL as test samples, and then each test sample was tested with reference to the detection method of Example 10. The statistical test results are shown in Table 1.

[0095] Table 1 Kit sensitivity test

[0096]

[0097] Note: “+” in the table indicates positive, and “-” indicates negative / not detected.

[0098] As can be seen from the results in Table 1, the kit I of the present invention has the highest sensitivity, and can detect samples with a minimum concentration of 0.1 ng / mL. Compared with kits IV to VIII, the sensitivity of kits I to III is significantly higher, which indicates that the magnetic particles of the present invention can improve the detection sensitivity of the kit.

[0099] Embodiment 12:

[0100] In this example, 50 blood samples collected clinically were tested using Kit I and Kits IV to VIII, respectively, and Kit IX: Monoclonal Antibody Against HCV Core (CP9), Hyb-9380B (column-filtrated) Kit (Special Immunology Research Institute) was used as a standard for testing. The results are shown in Tables 2 and 3.

[0101] Table 2 Kit Accuracy Test

[0102]

[0103] Note: “+” in the table indicates positive, and “-” indicates negative / not detected.

[0104] Table 3 Kit Accuracy Test

[0105]

[0106] Note: “+” in the table indicates positive, and “-” indicates negative / not detected.

[0107] By testing 50 clinical samples, the test results were statistically analyzed and the detection rate of each kit was calculated based on the detection results of kit IX:

[0108] Detection rate = (1-number of undetected samples / 50)*100%.

[0109] It can be seen from the results in Tables 2 and 3 that the detection rate of the kit of the present invention is 98%, which is close to the result of the standard kit IX and significantly higher than the detection rates of kits IV to VIII.

[0110] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. A kit for detecting hepatitis C core antigen, It is characterized in that The kit comprises the following components: Magnetic particle system: 0.1-0.2 M PBS buffer with pH=7.4-7.8 of magnetic particles and anti-HCV-cAg antibody conjugate; Enzyme labeling system: HRP-labeled anti-HCV-cAg antibody in 0.1-0.2 M PBS buffer with pH=7.4-7.8; Luminescent substrate I: a mixture of 2.0-4.0 mmol / L luminol and 0.2-0.4 mmol / L p-iodophenol; Luminescent substrate II: 5-10 mmol / L hydrogen peroxide; The method for preparing the magnetic particles comprises the following steps: The magnetic nanoparticles are ultrasonically dispersed in N,N-dimethylformamide, citric acid is added, and microwave treatment is performed at a power of 600 to 1000 W for 10 to 30 minutes, followed by filtering, washing and drying to obtain modified magnetic nanoparticles; The modified magnetic nanoparticles are placed in a boron-containing mixed solution for ultrasonic treatment for 8 to 10 hours, during which ozone is continuously introduced, and then filtered, washed and dried to obtain modified magnetic nanoparticles doped with boron oxide; Chitosan is dissolved in a hydrochloric acid solution with a volume fraction of 3-5% to obtain an acidified chitosan solution with a mass fraction of 5-10%, and then the modified magnetic nanoparticles doped with boron oxide are added and stirred evenly. A cross-linking monomer and an initiator are added and stirred to react at 100-150°C for 6-10 hours. After the reaction is completed, it is allowed to stand for 10-12 hours, and then filtered and washed to obtain magnetic particles with a diameter of 1-5 μm.

2. The kit according to claim 1, It is characterized in that The magnetic nanoparticles are selected from Fe 3 O 4 , Fe 2 O 3 , any one of FeO.

3. The kit according to claim 1, It is characterized in that The citric acid is added in an amount with a mass ratio of 1 to 2:10 to the magnetic nanoparticles.

4. The kit according to claim 1, It is characterized in that The boron-containing mixed solution is a solution obtained by dissolving ammonium pentaborate and boric acid in water, wherein the ammonium pentaborate, boric acid and water are added in a mass ratio of 3: (5-10):

100.

5. The kit according to claim 1, It is characterized in that The boron oxide-doped modified magnetic nanoparticles are added in an amount with a mass ratio of 1:1 to 2 to chitosan.

6. The kit according to claim 1, It is characterized in that The crosslinking monomer is selected from any one of N,N'-alkylenebis(meth)acrylamide, ethylene glycol diacrylate or trimethylolpropane triacrylate.

7. The kit according to claim 1, It is characterized in that The initiator is selected from any one of cumene hydroperoxide, tert-butyl hydroperoxide and di-tert-butyl peroxide.

8. The kit according to claim 1, It is characterized in that The cross-linking monomer is added in an amount of 1 to 3:1 with respect to the mass ratio of the chitosan; and the added amount of the initiator is 0.3 to 0.5% of the mass of the cross-linking monomer.

9. The kit according to claim 1, It is characterized in that The kit further comprises a positive standard and a negative standard, wherein the positive standard comprises HCV-cAg antigen, and the negative standard comprises BSA.

Citation Information

Patent Citations

  • HCV core antigen detection kit based on magnetic micro-particle chemiluminescence method

    CN104360063A

  • Kit for combined detection of hepatitis C virus antigen and antibody through chemiluminescence

    CN104914244A

  • Magnetic microsphere capable of absorbing cadmium ions and complexes thereof, as well as preparation method, application method and regeneration method of magnetic microsphere

    CN105536741A

  • Novel preparation method of functionalized porous magnetic microspheres

    CN112175150A

  • Microporous plate, chemiluminescence kit and detection method for detecting anti-transmembrane protein antibody in serum of HCV infected person

    CN112255413A